A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017
ONCOLOGIC DRUGS ADVISORY COMMITTEE BRIEFING DOCUMENT Tisagenlecleucel (CTL019) for the TREATMENT OF PEDIATRIC AND YOUNG ADULT PA
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites | Cell Death & Disease
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
FDA Panel Unanimously Recommends Approval for Novartis' CAR-T Therapy CTL019
ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah | Fierce Pharma
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
Frontiers | Manufacturing and Management of CAR T-Cell Therapy in “COVID-19's Time”: Central Versus Point of Care Proposals
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy | Nature Communications
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Fred Hutch Statement Regarding FDA Briefing About CAR T-cell Therapy
FDA Introductory Remarks Tisagenlecleucel Novartis Pharmaceuticals Corporation
FDA Panel Votes Unanimously to Support Leukemia Gene-Therapy Treatment - WSJ
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Manufacturing News of Note—Novartis to have Cell Therapies make Kymriah in Australia; Piramal Pharma expands API plant in Canada | Fierce Pharma
The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19 - Cytotherapy
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Can CAR-T and gene therapy cures really sustain biopharma? Not for all, analyst says | Fierce Pharma
The Process of CAR-T Cell Therapy | Novartis
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
CAR T-cell treatment pathway: From patient identification to long-term management - touchONCOLOGY
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
